Oxo Chemie starts hepatitis C Phase II

Oxo (Fribourg, Switzerland) began an 80-patient Phase II trial in Germany and Hong Kong of Macrokine to treat chronic active hepatitis C virus. The trial will assess the effect of Macrokine on liver e...